Loading clinical trials...
Loading clinical trials...
Fecal Microbiota Transplantation Combined With QL1706, Bevacizumab, and XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis: A Prospective, Multi-center, Single-arm Phase II Study
Conditions
Interventions
FMT+QL1706+Bevacizumab+XELOX
Locations
1
China
The Second People's Hospital of Changzhou
Changzhou, China
Start Date
April 17, 2025
Primary Completion Date
February 1, 2027
Completion Date
February 1, 2027
Last Updated
January 2, 2026
NCT07321847
NCT06069960
Lead Sponsor
Hua Jiang
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions